Pharmaceutical composition comprising rapamycin 42-ester with 3-hydroxy-2-hydroxymethyl-2-methylpropionic acidCCI-779 as an antineoplastic agent

摘要

This invention provides the use of CCl-779 in the treatment of neoplasms.